1
|
Davila ML, Bouhassira DC, Park JH, Curran
KJ, Smith EL, Pegram HJ and Brentjens R: Chimeric antigen receptors
for the adoptive T cell therapy of hematologic malignancies. Int J
Hematol. 99:361–371. 2014. View Article : Google Scholar : PubMed/NCBI
|
2
|
Burga RA, Thorn M, Point GR, Guha P,
Nguyen CT, Licata LA, DeMatteo RP, Ayala A, Joseph Espat N,
Junghans RP and Katz SC: Liver myeloid-derived suppressor cells
expand in response to liver metastases in mice and inhibit the
anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother.
64:817–829. 2015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Katz SC, Point GR, Cunetta M, Thorn M,
Guha P, Espat NJ, Boutros C, Hanna N and Junghans RP: Regional
CAR-T cell infusions for peritoneal carcinomatosis are superior to
systemic delivery. Cancer Gene Ther. 23:142–148. 2016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Katz SC, Burga RA, McCormack E, Wang LJ,
Mooring W, Point GR, Khare PD, Thorn M, Ma Q, Stainken BF, et al:
Phase I hepatic immunotherapy for metastases study of
intra-arterial chimeric antigen receptor-modified T-cell therapy
for CEA+ liver metastases. Clin Cancer Res. 21:3149–3159. 2015.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Guo Y, Wang Y and Han W: Chimeric antigen
receptor-modified T cells for solid tumors: Challenges and
prospects. J Immunol Res. 2016:38508392016. View Article : Google Scholar : PubMed/NCBI
|
6
|
Barsoum IB, Smallwood CA, Siemens DR and
Graham CH: A mechanism of hypoxia-mediated escape from adaptive
immunity in cancer cells. Cancer Res. 74:665–674. 2014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Gabrilovich D: Mechanisms and functional
significance of tumourinduced dendritic-cell defects. Nat Rev
Immunol. 4:941–952. 2004. View
Article : Google Scholar : PubMed/NCBI
|
8
|
Greenhough A, Smartt HJ, Moore AE, Roberts
HR, Williams AC, Paraskeva C and Kaidi A: The COX-2/PGE2 pathway:
Key roles in the hallmarks of cancer and adaptation to the tumour
microenvironment. Carcinogenesis. 30:377–386. 2009. View Article : Google Scholar : PubMed/NCBI
|
9
|
Zhao XY, Chen TT, Xia L, Guo M, Xu Y, Yue
F, Jiang Y, Chen GQ and Zhao KW: Hypoxia inducible factor-1
mediates expression of galectin-1: The potential role in
migration/invasion of colorectal cancer cells. Carcinogenesis.
31:1367–1375. 2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Hao NB, Lü MH, Fan YH, Cao YL, Zhang ZR
and Yang SM: Macrophages in tumor microenvironments and the
progression of tumors. Clin Dev Immunol. 2012:9480982012.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Barsoum IB, Koti M, Siemens DR and Graham
CH: Mechanisms of hypoxia-mediated immune escape in cancer. Cancer
Res. 74:7185–7190. 2014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Sun H, Luo G, Chen D and Xiang Z: A
comprehensive and system review for the pharmacological mechanism
of action of rhein, an active anthraquinone ingredient. Front
Pharmacol. 7:2472016. View Article : Google Scholar : PubMed/NCBI
|
13
|
Hu L, Cui R, Liu H and Wang F: Emodin and
rhein decrease levels of hypoxia-inducible factor-1α in human
pancreatic cancer cells and attenuate cancer cachexia in athymic
mice carrying these cells. Oncotarget. 8:88008–88020. 2017.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Ma F, Hu L, Yu M and Wang F: Emodin
decreases hepatic hypoxia-inducible factor-1α by inhibiting its
biosynthesis. Am J Chin Med. 44:997–1008. 2016. View Article : Google Scholar : PubMed/NCBI
|
15
|
Wang F, Li SS, Segersvärd R, Strömmer L,
Sundqvist KG, Holgersson J and Permert J: Hypoxia inducible
factor-1 mediates effects of insulin on pancreatic cancer cells and
disturbs host energy homeostasis. Am J Pathol. 170:469–477. 2007.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Zhang X, Yang Y, Zhang L, Lu Y, Zhang Q,
Fan D, Zhang Y, Zhang Y, Ye Z and Xiong D: Mesenchymal stromal
cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for
the treatment of B cell lymphoma combined with IDO pathway
inhibitor D-1-methyl-tryptophan. J Hematol Oncol. 10:562017.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Xu Y, Chaudhury A, Zhang M, Savoldo B,
Metelitsa LS, Rodgers J, Yustein JT, Neilson JR and Dotti G:
Glycolysis determines dichotomous regulation of T cell subsets in
hypoxia. J Clin Invest. 126:2678–2688. 2016. View Article : Google Scholar : PubMed/NCBI
|
19
|
Ottensmeier CH, Perry KL, Harden EL,
Stasakova J, Jenei V, Fleming J, Wood O, Woo J, Woelk CH, Thomas GJ
and Thirdborough SM: Upregulated glucose metabolism correlates
inversely with CD8+ T-cell infiltration and survival in squamous
cell carcinoma. Cancer Res. 76:4136–4148. 2016. View Article : Google Scholar : PubMed/NCBI
|
20
|
Tao JH, Barbi J and Pan F:
Hypoxia-inducible factors in T lymphocyte differentiation and
function. A review in the theme: Cellular responses to hypoxia. Am
J Physiol Cell Physiol. 309:C580–C589. 2015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Sukumar M, Liu J, Ji Y, Subramanian M,
Crompton JG, Yu Z, Roychoudhuri R, Palmer DC, Muranski P, Karoly
ED, et al: Inhibiting glycolytic metabolism enhances CD8+ T cell
memory and antitumor function. J Clin Invest. 123:4479–4488. 2013.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Kheshtchin N, Arab S, Ajami M, Mirzaei R,
Ashourpour M, Mousavi N, Khosravianfar N, Jadidi-Niaragh F, Namdar
A, Noorbakhsh F, et al: Inhibition of HIF-1α enhances anti-tumor
effects of dendritic cell-based vaccination in a mouse model of
breast cancer. Cancer Immunol Immunother. 65:1159–1167. 2016.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Doedens AL, Stockmann C, Rubinstein MP,
Liao D, Zhang N, DeNardo DG, Coussens LM, Karin M, Goldrath AW and
Johnson RS: Macrophage expression of hypoxia-inducible factor-1
alpha suppresses T-cell function and promotes tumor progression.
Cancer Res. 70:7465–7475. 2010. View Article : Google Scholar : PubMed/NCBI
|
24
|
Noman MZ, Desantis G, Janji B, Hasmim M,
Karray S, Dessen P, Bronte V and Chouaib S: PD-L1 is a novel direct
target of HIF-1α and its blockade under hypoxia enhanced
MDSC-mediated T cell activation. J Exp Med. 211:781–790. 2014.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Clambey ET, McNamee EN, Westrich JA,
Glover LE, Campbell EL, Jedlicka P, de Zoeten EF, Cambier JC,
Stenmark KR, Colgan SP and Eltzschig HK: Hypoxia-inducible factor-1
alpha-dependent induction of FoxP3 drives regulatory T-cell
abundance and function during inflammatory hypoxia of the mucosa.
Proc Natl Acad Sci USA. 109:E2784–2793. 2012. View Article : Google Scholar : PubMed/NCBI
|